Introduction {#s1}
============

Genome-wide association studies (GWAS) increasingly implicate common variation in the human genome with traits and complex diseases, including traits reflecting cardiac conduction properties. The majority of trait-associated genetic variants (single nucleotide polymorphisms; SNPs) is found in noncoding genomic DNA, and is thought to affect the function of *cis-*regulatory elements (REs) controlling the activity of their target gene promoters ([@bib24]; [@bib51]; [@bib71]). Expression quantitative trait locus (eQTL) analyses show that common variation can lead to both down- and upregulation of target gene expression ([@bib31]; [@bib37]; [@bib68]). Yet, the mechanisms underlying the effect of such variation on RE function and gene expression are poorly understood.

The atrioventricular conduction system (AVCS) conducts the electrical impulse from atria to ventricles and synchronizes ventricular activation, thus orchestrating the rhythm of the heart. Disrupted AVCS function can lead to life-threatening cardiac arrhythmias and hypertrophy ([@bib2]; [@bib19]). Common SNPs in the gene desert upstream of *TBX3* have been strongly associated with both PR interval and QRS duration ([@bib61]; [@bib74]; [@bib76]; [@bib81]; [@bib83]), ECG parameters directly reflective of AVCS function and representing the time between the first moment of activation of the atria and the ventricles, and ventricular activation, respectively. The T-box transcription factor 3 (Tbx3) is specifically expressed in the AVCS, including the AV node, AV bundle and proximal bundle branches, and plays a critical role in its development and function ([@bib8]; [@bib7]; [@bib26]; [@bib73]). Presumably, the SNPs upstream of *TBX3* affect the expression of *TBX3* or other nearby genes, such as *TBX5*, which also plays a key role in AVCS development and function ([@bib5]; [@bib15]), or *MED13L*, encoding a subunit of the ubiquitously expressed Mediator complex involved in transcriptional activation ([@bib6]; [@bib80]) and recently implicated in heart rate recovery after exercise ([@bib65]; [@bib84]).

Efforts to elucidate the mechanisms underlying the transcriptional regulation of AVCS genes and the role of genetic variation are challenging, as the availability of relevant cells for functional and (epi)genomic experiments is hampered by the very small proportion of *TBX3*^+^ AVCS cardiomyocytes in the heart and the heterogeneous cellular composition of the AVCS ([@bib1]; [@bib34]). Along this line, eQTL data for *TBX3* in cardiac tissue is not available, and AVCS tissue from human hearts is not expected to become available soon. Moreover, suitable AVCS-like cell lines, derived from stem cells or immortalized primary cells do not exist. Current cardiac epigenomic datasets from humans are mainly derived from whole heart or heart compartment tissue and are not suitable for the identification of AVCS REs, as the proportion of AVCS cells in these tissues is extremely small.

In this study, we aimed at circumventing the unavailability of AVCS cells to elucidate how the PR interval- and QRS duration-associated variants in the gene desert in-between *TBX3* and *MED13L* affect the regulation of gene expression and AVCS function. Utilizing mouse AVCS-specific assay for transposase-accessible chromatin sequencing (ATAC-seq) and human and mouse *TBX3/TBX5* locus-wide self-transcribing active regulatory region sequencing (STARR-seq), we identified multiple regulatory regions within two risk loci upstream of *TBX3* that are activated by factors involved in AVCS development and drive gene expression in vitro. We assessed the presence of associated variants in these REs and tested their effect on RE activity. Using modified BACs containing the mouse orthologues of the respective risk loci, we show that each region independently drives reporter expression in the AVCS in transgenic mice. We deleted the mouse homologous regions of both human risk loci using CRISPR/Cas9-mediated genome editing and show that deletion of the proximal domain resulted in a two-fold increase in the expression of *Tbx3,* but not *Tbx5* or *Med13l,* specifically in the AVCS, and in decreased PR interval and increased QRS duration. Thus, we used a systematic approach to identify REs driving *TBX3* expression in the small number of cells that make up the AVCS, and provide evidence that a genomic noncoding region associated with PR interval is involved in the regulation of *Tbx3* expression and AVCS function in vivo.

Results {#s2}
=======

GWAS variation in gene desert upstream of TBX3 {#s2-1}
----------------------------------------------

Common genomic variants associated with PR interval and QRS duration have been identified in the region of the human *TBX3/TBX5* gene cluster ([@bib61]; [@bib74]; [@bib76]; [@bib81]). Using publicly available human Hi-C data, we defined the topologically associating domain (TAD) of this gene cluster. *TBX3* and its upstream gene desert are organized in a TAD of approximately 1.3 Mb that is delimited by binding sites for CCCTC-binding factor (CTCF; a zinc-finger protein associated with enhancer-promoter looping and TAD boundary formation \[[@bib23]; [@bib57]\]) and physically separated from that of the neighboring gene *MED13L,* corresponding to the organization of the murine loci in cardiac embryonic tissue ([@bib82]; [Figure 1A](#fig1){ref-type="fig"}). Sequences within the TADs of *TBX3* and *TBX5* physically interact with each other to some extent. To delineate the GWAS risk loci, we mapped the associated variants to the human reference genome. Variants associated with both PR interval ([@bib81]) and QRS duration ([@bib76]) are located in a region approximately −261 kb to −221 kb upstream of *TBX3* (variant region (VR) 1). A second region (VR2) ranging from −85 kb to −6 kb upstream of *TBX3* harbors SNPs associated with only PR interval. SNPs associated with QRS duration were also found downstream of *TBX3.* The location of these variants within the *TBX3* TAD suggests that they may affect putative REs that regulate the expression of *TBX3* and possibly *TBX5* in the heart, causing affected conduction parameters.

![Identification of AVCS-specific accessible chromatin within the *Tbx3* locus harboring GWAS-associated variant regions.\
(**A**) UCSC genome browser view depicts the genomic location of human *TBX3* and neighboring genes. GWAS SNPs associated with PR interval ([@bib81]) and QRS duration ([@bib76]) are plotted as --log10 of their p-values (lower cut-off 1.3 (p=0.05)) and depict two variant regions (VR1 and VR2) upstream of *TBX3*. CTCF ChIP-seq track shows binding sites for CTCF, corresponding to the boundaries of the topologically associating domains. The Hi-C map is derived from a human lymphoblastoid cell line ([@bib66]) and reveals separated domains for *TBX3* and neighboring *MED13L* and *TBX5* (dark grey dashed lines). Within the *TBX3/TBX5* TAD, the *TBX3* and *TBX5* loci form sub-TADs (light grey dashed lines). (**B**) Genome browser view depicting embryonic Tbx3^+^ AVCS-specific (ATAC_AVCS) and ventricular (ATAC Ventricle) accessible chromatin regions ([@bib78]) within the murine *Tbx3* locus. AVCS and Ventricle RE candidates depict selected ATAC regions. (**C**) HOMER motif enrichment analysis on 67 AVCS and Ventricle ATAC regions (depicted in **B**) reveals binding motifs for Smad, Gata and Tcf factors are enriched in AV junction accessible regions compared to ventricular accessible regions. (**D**) Overlap of 67 ATAC_AVJ regions within *Tbx3* locus with 67 ATAC-ventricle regions.](elife-56697-fig1){#fig1}

Identification of accessible regulatory elements within the murine Tbx3 locus {#s2-2}
-----------------------------------------------------------------------------

To identify REs driving *Tbx3* expression in the AVCS that are possibly affected by genetic variation within VR1 and VR2, we performed ATAC-seq (assay for transposase-accessible chromatin, followed by sequencing) ([@bib14]) on *Tbx3*+ FACS-purified AVCS cardiomyocytes from murine E13.5 *Tbx3*^Venus/+^ microdissected AV junctions. 67 genomic regions within the *Tbx3/Tbx5* regulatory domain, as determined by chromatin conformation capture ([@bib82]), are accessible in AVCS cardiomyocytes, including the previously identified AV canal enhancers Tbx3-eA and Tbx3-eB ([@bib82]; [Figure 1B](#fig1){ref-type="fig"}). To identify transcription factors potentially involved in the regulation of *Tbx3* in the AVCS, we performed a motif enrichment analysis on the 67 regions within the *Tbx3* locus and compared it to the analysis of an equal number of accessible regions in ventricular tissue within the locus ([@bib78]). Among the highest scoring binding motifs in embryonic AVCS cells are motifs for transcription factors important for cardiogenesis, including Hand2, Sox9 and Tbx20 ([Figure 1C](#fig1){ref-type="fig"}). Interestingly, AVCS-specific accessible sequences were enriched for motifs for members of the Smad and Gata families of transcription factors (Smad2-4, Gata4/6), involved in the activation of regulatory sequences (including Tbx3-eA) specifically in the AV canal ([@bib75]), and for Tcf factors (Tcf4, Tcf3) acting downstream of canonical Wnt-signaling to regulate AV canal specification ([@bib28]; [Figure 1C](#fig1){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 1). Of the 67 AVCS regions, 28 overlapped with accessible ventricular regions ([Figure 1D](#fig1){ref-type="fig"}). Analysis of enriched motifs in the 39 AVCS- or ventricle-specific regions did not result in more pronounced tissue-specificity (not shown), prompting us to continue with the 67 AVCS regions for further analysis.

Identification of active regulatory sequences in the mouse and human TBX3 locus {#s2-3}
-------------------------------------------------------------------------------

The lack of AVCS-specific epigenomic datasets from mouse or human tissue and the absence of readily available human AVCS-relevant cells hamper efforts to identify relevant REs. To overcome this deficit, we utilized our finding that AVCS-accessible regions within the *Tbx3* locus are enriched for binding sites for Smad/Gata and Tcf (Wnt) transcription factor binding, involved in AVCS gene regulation ([@bib28]; [@bib75]). Using bacterial artificial chromosomes (BACs) spanning the entire human (+ / - 1.3 Mb; 17 BACs) and murine (+ / - 1 Mb; 11 BACs) *TBX3* locus, we performed self-transcribing active regulatory region-sequencing (STARR-seq) ([@bib3]) to scan for regulatory potential locus-wide ([Figure 2A](#fig2){ref-type="fig"}). The sequenced input libraries revealed an evenly distributed coverage throughout the locus, indicating that the entire locus is sufficiently and to an equal extent represented in the libraries (DNA input; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Regions where two BACs overlap show an approximate doubling of the number of sequencing reads.

![Validation and characterization of STARR-seq datasets.\
(**A**) Overview of the STARR-seq procedure on the murine/human *TBX3/TBX5* locus. BACs spanning the entire murine or human *TBX3/TBX5* locus are sheared to fragments of approximately 500--1000 bp. Fragments are recombined in the pSTARR expression vector to generate the STARR-seq libraries, which are transfected in cells with or without stimulation, that is with pcDNA (control) or expression vectors for Smad/Gata or Tcf factors. Two days after transfection, total RNA is isolated from all cells. mRNA transcripts are isolated from the pool of total RNA and next-generation sequenced on an Illumina MiSeq. Reads are mapped to the respective genomes. Comparison of stimulated over control data yields stimulus-responsive REs. (**B**) Overview of the human *TBX3/TBX5* locus with STARR-seq tracks for hSTARR_SG4 (SG4-vs-ctrl) and hSTARR_Wnt (Wnt-vs-ctrl). The displayed tracks represent log2 fold changes of enrichment of SG4/Wnt-stimulated regions over the unstimulated control. (**C,D**) Functional conservation of STARR-seq activity between murine and human fragments. Overlap of translated (mm9 to hg19) mSTARR_SG4 (160/216) (**C**) or mSTARR_Wnt (172/253) (**D**) regions with human hSTARR_SG4/Wnt regions. (**E**) Correlation between STARR-seq activities of replicate hSTARR_SG4 transfections in COS-7 cells. X- and y-axis depict log2 of the fold change of replicate 1 and replicate 2, respectively. (**F**) Genome browser views of hSTARR tracks for replicate transfections of libraries in COS-7 cells with co-transfection of SG4 factors show reproducibility of STARR-seq data. (**G**) Validation of selected active (log2FC \>0.58 (FC \>1.5)) hSTARR (n = 10), mSTARR (n = 9) and negative h/mSTARR (FC \<1.5; n = 10) regions by luciferase assay. Y-axis represents percentage of tested fragments with activity in luciferase assay (FC \>2 of reporter activity over empty vector). (**H**) Relative luciferase activity (RLA) of pGL4-(Tbx2)~4~ (top) and the ratio of luciferase activity of TOP over FOP reporter (bottom) upon co-transfection with pcDNA ('-') and SG4- and Tcf-factors, respectively. Transfection in COS-7 cells; n = 4. (**I,J**) Overlap of mSTARR_SG4/Wnt regions with ATAC_AVCS regions (**I**) and of hSTARR_SG4/Wnt with hEMERGE regions (**J**). (**K**) HOMER motif enrichment analysis on human and murine STARR_SG4 and STARR_Wnt active (log2FC \>0/58 (FC \>1.5)) regions. Binding motifs for Smad/Gata factors are generally more enriched in STARR_SG4 regions, whereas STARR_Wnt regions are more enriched for motifs for Tcf factors in both human and murine datasets.](elife-56697-fig2){#fig2}

As AVCS-like cells are not available for large-scale and high-efficiency transfections, we transfected our STARR-seq libraries in COS-7 cells (a monkey kidney-derived fibroblast cell line), allowing us to assess the response of sequences within the libraries with high transfection efficiency specifically to the co-transfected transcription factors. Co-transfection of the libraries with pcDNA3.1 as control (m/hSTARR_ctrl) revealed multiple active sequences, indicative of REs capable of driving reporter gene expression in COS-7 cells ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). To find Smad/Gata and Wnt-responsive REs, we co-transfected the murine and human STARR libraries with Smad/Gata factors (m/hSTARR_SG4) or with Tcf-factors (m/hSTARR_Wnt), respectively. Regions with a log2 fold change of \>0.58 (fold change \>1.5) of SG4/Wnt-co-transfected activity over pcDNA-co-transfected activity were considered to activate transcription. Combined, we found 216 SG4- and 257 Wnt-responsive regions in the murine locus, and 206 SG4- and 190 Wnt-responsive regions in the human locus ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The transcriptional potential of approximately 20% of the active mSTARR regions for both SG4- and Wnt-stimulation was functionally conserved between mouse and human, as the human homologues of these regions were active in the respective human STARR-seq libraries as well ([Figure 2C,D](#fig2){ref-type="fig"}). Duplicate transfections showed a strong correlation ([Figure 2E,F](#fig2){ref-type="fig"}). We performed transient transfection in COS-7 followed by luciferase assays with a subset of the identified regions to validate their regulatory potential. 84% of m/hSTARR regions (n = 19) drove luciferase activity \>2 fold relative to the vector containing only the core promoter, compared to 10% of randomly selected negative regions (n = 10; m/hSTARR fold change \<1.5; p=0.0007 (two-sample t-test)) ([Figure 2G](#fig2){ref-type="fig"}). These data confirm the positive signals (\>1.5 fold over control) in STARR-seq represent fragments with enhancer activity. Among the active regions are both human and murine homologues of Tbx3-eA and Tbx3-eB. pGL4-(Tbx2)~4~ (tandem repeat of a 380 bp Tbx2 enhancer responding to Smad- and Gata4 factors) ([@bib75]) and TOP/FOP (Wnt-signaling responsive TCF/LEF reporter assay) reporters showed strong luciferase activity upon stimulation with SG4- and Tcf-factors, respectively, validating that these factors activate SG4- and Tcf-responsive sequences upon transfection ([Figure 2H](#fig2){ref-type="fig"}). A subset of the active regions from mSTARR_SG4 and from mSTARR_Wnt overlapped both each other and ATAC_AVCS regions ([Figure 2I](#fig2){ref-type="fig"}), indicative of genomic regions both capable of activating reporter gene expression and being accessible in AVCS tissue. Similarly, a subset of hSTARR_SG4 and hSTARR_Wnt regions overlapped both each other and human EMERGE regions ([Figure 2J](#fig2){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 2B).

To further justify the legitimacy of the chosen \>1.5 threshold for fold activity and to validate that the identified regions were indeed activated by either SG4- or Wnt-factors, we performed transcription factor motif enrichment analysis and found that the 216 mSTARR_SG4 sequences were enriched for binding motifs for Smad and Gata factors when compared to an equal number of randomly selected mSTARR_Wnt active sequences. Vice versa, binding motifs for Tcf factors are enriched in the 257 mSTARR_Wnt regions when compared to mSTARR_SG4 regions ([Figure 2K](#fig2){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 2A). These results indicate that 1) the regions we identified in the different libraries are activated by the respective cotransfected factors and 2) the threshold for regulatory activity of \>1.5 fold change used to filter and select these regions is justified. Combined, these results suggest that multiple regions within both the human and murine *TBX3* locus are accessible specifically in AVCS tissue and respond to Smad/Gata and Wnt-signaling to activate reporter gene expression, indicating they are potentially involved in *TBX3* regulation in the AVCS in vivo.

Identification of variant REs within VR1 and VR2 {#s2-4}
------------------------------------------------

For the identification of regulatory sequences throughout the human *TBX3* locus potentially involved in AVCS-specific gene expression, we used three approaches. First, we combined the human STARR-seq regions activated by either SG4- or Tcf-factors throughout the *TBX3* locus, resulting in 254 *h*STARR-REs ([Figure 3A](#fig3){ref-type="fig"}). Second, although epigenomic data from human AVCS tissue is scarce, we used cardiac-specific EMERGE enhancer prediction ([@bib77]) and found 24 putative cardiac-specific *h*EMERGE REs within the *TBX3* locus ([Figure 3B](#fig3){ref-type="fig"}). Third, we translated and mapped the genomic sequences of the 67 *m*ATAC_AVJ regions and of the cardiac-specific mouse EMERGE predicted enhancers to the human genome, resulting in 62 mouse orthologous regions ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). Combined, this approach resulted in 296 candidate RE regions in the human *TBX3* locus, based on sequence activity (hSTARR), enhancer prediction based on various cardiac-specific epigenomic datasets (hEMERGE), and conservation with active and AVCS-specific accessible genomic regions from the mouse genome (mouse orthologous regions) ([Figure 3D](#fig3){ref-type="fig"}). The previously identified human enhancer Tbx3-eA, driving AVCS expression and responding to Smad/Gata stimulation in vitro ([@bib82]), is marked by all three criteria, supporting the validity of our approach ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}.

![Approach for the identification of candidate REs potentially affected by GWAS variation.\
(**A**) Active STARR regions within the human *TBX3* locus, responding to either SG4- or Tcf-factors. Log2 ratios of the fold change of SG4- or Tcf-stimulated respons to pcDNA is depicted. Blue bars represent active regions (fold change \>1.5) included for further analysis. (**B**) EMERGE enhancer prediction track (black) with selected enhancer candidates (red bars) included for further analysis. (**C**) Identification of candidate REs within the mouse *Tbx3* locus. Regions were selected based on ATAC_AVCS (top black track) and mouse EMERGE enhancer prediction (bottom black track). Selected regions (black bars) were translated to and plotted onto the human genome and included for further analysis. (**D**) Final RE candidate regions within the human *TBX3* based on the three criteria listed above. Blue bars: hSTARR regions; red bars: human EMERGE regions; black bars: mouse orthologous candidate regions translated to human genome. (**E**) Overlap of candidate regions from (**D**) within VR1 and VR2 with GWAS SNPs leads to final list of RE candidates potentially affected by GWAS variation.](elife-56697-fig3){#fig3}

To assess whether these RE candidates harbor common variants associated with PR interval or QRS duration, we filtered for genomic location within VR1 or VR2 and found seven candidate variant REs within human VR1 and 13 candidate variant REs within VR2 ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 5). To assess the regulatory potential of the candidate REs and to elucidate whether their activity is affected by genomic variation, we overlapped these REs with PR interval- or QRS duration-associated variants (p\>0.05) ([@bib76]; [@bib81]), or variants in linkage disequilibrium (LD) with the most significantly associated variants within both regions (r^2^ \>0.5; [Figure 3E](#fig3){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 4). Combined, we found six candidate REs in VR1 and 6 candidate REs in VR2 harboring one or multiple variants ([Figure 3E](#fig3){ref-type="fig"}).

We measured luciferase reporter activity of the major and minor haplotype of these RE candidates and found that all RE candidates except for *h*RE5 drove basal luciferase reporter activity in both HL-1 and COS-7 cells (n = 4; p\<0.05); *h*RE5 decreased reporter activity ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Due to technical issues *h*RE13 was omitted from downstream experiments. We next measured regulatory activity of the risk and reference haplotypes for each RE. The risk allele of 4 REs (*h*RE5, *h*RE7, *h*RE8 and *h*RE18) increased basal reporter activity in HL-1 cells when compared to the reference allele, whereas the risk allele of *h*RE9, *h*RE11 and *h*RE15-16 decreased basal reporter activity in both HL-1 and COS-7 cells ([Figure 4A](#fig4){ref-type="fig"}). The risk allele of a subset of these regions also affected their SG4-/Wnt-induced activity ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). The SG4-dependent activity of *h*RE3 and *h*RE9 and the Wnt-dependent activity of *h*RE6 was increased by the risk allele, whereas the risk allele of *h*RE8, *h*RE15-16 and *h*RE18 decreased both SG4- and Wnt-dependent activity (*h*RE8, *h*RE18), or only Wnt-response (*h*RE15-16). Combined, these results show that multiple candidate REs within both VR1 and VR2 hold regulatory capacity in vitro, and that the activity of a subset of these regions (in both VR1 and VR2) is affected by the risk allele. We next analyzed whether potential TF binding motifs were disrupted or de novo created by the respective SNP in the variant region of the functionally affected REs to elucidate, thereby possibly explaining the differential effect of the risk allele on luciferase activity. None of the variants within the functionally affected fragments matched known TF binding motifs.

![Identification of functional variants affecting RE candidate activity within human VR1 and VR2.\
(**A**) Basal luciferase activity of the reference and alternative alleles for each RE candidate in HL-1 and COS-7 cells. Luciferase activities were normalized to the activity of the reference allele for each fragment, in both HL-1 and COS-7 cells. (**B**) Relative luciferase activity of the reference and alternative alleles for each RE candidate upon stimulation with Smad- and Gata4 factors (SG4) and Tcf+LiCl factors (Wnt) in COS-7 cells. SG4/Wnt activity of the alternative alleles were normalized to the respective activity of the reference allele for each RE candidate. Transfections were performed in duplicates and replicated twice. Error bars represent standard deviations. \*: p\<0.05 (Student's t-test).](elife-56697-fig4){#fig4}

Genomic regions upstream of TBX3 drive AVCS expression {#s2-5}
------------------------------------------------------

The murine region homologous to human VR2 is located within a region that we previously demonstrated to harbor sequences driving *Tbx3* expression in the ventral, right-sided and dorsal (primordial AV node) aspect of the AV canal (BAC 366H17-GFP; −82 kb to +78 kb relative to *Tbx3*; [Figure 5](#fig5){ref-type="fig"}; [@bib82]).Sequences within VR1 and VR2 are to a large extent evolutionary conserved between human and mouse, and VR2 harbors the AVC-specific RE (Tbx3-eA) that was functionally and structurally conserved between mouse and human ([@bib82]; [Figure 5A,B](#fig5){ref-type="fig"}).To elucidate the involvement of the distal variant region (VR1) in the regulation of cardiac *Tbx3* expression, we set out to probe this domain for its regulatory potential by modifying a BAC spanning −245 kb to −75 kb upstream of *Tbx3* (459M16-GFP; [Figure 5B](#fig5){ref-type="fig"}). Although this BAC does not overlap VR2 and does not contain the previously identified RE (Tbx3-eA) driving AV node expression ([@bib82]), immunohistochemistry on sections of *Tbx3*-459M16-GFP E14.5 embryos revealed GFP reporter expression throughout the entire AVCS in a pattern resembling that of endogenous *Tbx3*, including the full AV canal and prospective AV node, AV bundle and BBs ([Figure 5C](#fig5){ref-type="fig"}). Furthermore, expression was found in the eye, ear, genital tubercle, limbs, and mammary glands ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This expression pattern is similar to that of previously described BAC 89K7-GFP, which only partially overlaps 459M16 and contains *Tbx3* and both the synergistically acting REs Tbx3-eA and Tbx3-eB ([@bib82]; [Figure 5D](#fig5){ref-type="fig"}). These observations suggest that multiple physically separated regulatory regions independently drive AVCS expression ([Figure 5E](#fig5){ref-type="fig"}).

![VR1 and VR2 are located within regulatory domains that redundantly drive AVCS expression.\
(**A**) Zoom-in of the human *TBX3* locus depicting distal variant region VR1, harboring SNPs for both PR interval and QRS duration, and proximal variant region VR2, harboring SNPs for PR interval. Mouse conservation (green) depicts genomic sequences conserved in the mouse genome; GERP depicts evolutionary constraint of genomic regions. (**B**) Homologous murine region within the *Tbx3* locus corresponding to the region depicted in (**A**). Homologous regions of VR1 and VR2 are depicted. Dark grey lines depict the locations of GFP-modified BACs, harboring either only VR2 (143N21, 366H17), both VR1 and VR2 (89K7) or only VR1 (459M16). (**C**) Immunohistochemistry on section through E14.5 459M16-GFP heart shows GFP reporter gene expression throughout the entire AVCS (white arrows). The Hcn4^+^ sinoatrial node does not express GFP. (**D**) Schematic overview of GFP-expression domains of BACs depicted in (**B**). The genomic region spanned by BACs 89K7 and 459M16, both harboring VR1, harbors regulatory elements driving expression throughout the complete AVCS including the atrioventricular bundle. The genomic region spanned by BACs 143N21 and 366H17 drive partial AVCS expression, not including left atrioventricular ring bundle and atrioventricular bundle expression. (**E**) Model of the topology of the *Tbx3* locus, depicting VR1 and VR2 both involved in regulation of *Tbx3* in the AV conduction system. Genomic sequences involved in the expression of *Tbx3* in the sinoatrial node are absent from these regions and likely reside more distally (grey dashed line). avb, atrioventricular bundle; avn, atrioventricular node; la, left atrium; lv, left ventricle; ra, right atrium; ravrb, right atrioventricular ring bundle; rv, right ventricle.](elife-56697-fig5){#fig5}

Analysis of the function of VR1 and VR2 in vivo {#s2-6}
-----------------------------------------------

To analyze the involvement of VR1 in endogenous regulation of gene expression and heart function, we used TALEN-mediated genome editing to delete the 69 kb homologous region (−245 kb to −176 kb relative to *Tbx3*) from the murine genome (*Tbx3^∆VR1^*; [Figure 6A](#fig6){ref-type="fig"}). We validated the deletion by PCR and Sanger sequencing ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). *Tbx3^+/+^, Tbx3^ΔVR1/+^* and *Tbx3^ΔVR1/ΔVR1^* mice were born according to Mendelian ratios ([Figure 6B](#fig6){ref-type="fig"}). We measured expression levels in microdissected AV junctions (containing the AV node and AV bundle) of E13.5 *Tbx3^+/+^* and *Tbx3^ΔVR1/ΔVR1^* hearts and found that expression of *Tbx3* or neighboring *Med13l* and *Tbx5* was not affected ([Figure 6C](#fig6){ref-type="fig"}, not shown for *Med13l* and *Tbx5*). To elucidate whether deletion of VR1 affects AVCS function postnatally, we performed surface ECGs on adult *Tbx3^+/+^* and *Tbx3^ΔVR1/ΔVR1^* mice and found no difference in PR interval or QRS duration between genotypes (*Tbx3^+/+^* n = 10, *Tbx3^ΔVR1/+^* n = 12, *Tbx3^ΔVR1/ΔVR1^* n = 9; [Figure 6---figure supplement 2A--C](#fig6s2){ref-type="fig"}). To exclude a possible rescue effect of the sympathetic nervous system on AVCS function in the absence of VR1, we measured conduction parameters by ex vivo ECG recordings on Langendorff perfused hearts and again found no difference between *Tbx3^+/+^* and *Tbx3^ΔVR1/ΔVR1^* hearts ([Figure 6---figure supplement 2D,E](#fig6s2){ref-type="fig"}).

![Genomic deletion of VR1 and VR2 in vivo.\
(**A**) Mouse genomic regions targeted by TALEN- (VR1) or CRISPR-Cas9- (VR2) mediated genome editing. (**B**) Genotype ratios of ∆VR1 mutant and wildtype born pups, depicted as percentage of total number of pups. (**C**) Relative expression levels of *Tbx3* in *Tbx3^+/+^* (n = 8) and *Tbx3^∆VR1/∆VR1^* (n = 12) microdissected E13.5 AV junctions. Expression levels are normalized to the expression of *Tbx2.* (**D**) Genotype ratios of ∆VR2 mutant and wildtype born pups, depicted as percentage of total number of pups, revealing the number of *Tbx3^∆VR2/∆VR2^* pups is lower than expected according to Mendelian ratios (\*: p\<0.01). (**E**) Relative expression levels of *Tbx3* in *Tbx3^+/+^* (n = 8) and *Tbx3^∆VR2/∆VR2^* (n = 9) microdissected E13.5 AV junctions, revealing increased expression of *Tbx3* in *Tbx3^∆VR2/∆VR2^* mutants (p\<0.05). Expression levels are normalized to the expression of *Tbx2.* (**F**) Expression levels of target genes of *Tbx3* in microdissected E13.5 AV junctions, expression levels of neighboring genes in microdissected E13.5 AV junctions, and expression levels of *Tbx3* in other tissues in which Tbx3 is expressed, in *Tbx3^+/+^* (n = 8) and *Tbx3^∆VR2/∆VR2^* (n = 9) E13.5 embryos. Expression levels were normalized to the expression of *Tbx2* (AV junctions), *Isl1* (SAN) or *Hprt* (lung, limb, liver). \*:p\<0.05. (**G**) In-situ hybridization on sections of *Tbx3^+/+^* and *Tbx3^∆VR2/∆VR2^* E13.5 hearts shows expression of Tbx3 in the cardiac conduction system, including the sinoatrial node, atrioventricular canal, atrioventricular bundle and bundle branches. The expression pattern is not affected in *Tbx3^∆VR2/∆VR2^* hearts. (**H,I**) PR interval (**H**) and QRS duration (**I**) in *Tbx3^+/+^* (WT; n = 8) and *Tbx3^∆VR2/∆VR2^* (hom; n = 8) mice measured by surface ECG on male mice (2--4 months old). \*:p\<0.05. avb, atrioventricular bundle; avc, atrioventricular canal; cgn, cardiac ganglia; la, left atrium; lsh, left sinus horn; lu, lung; lv, left ventricle; ra, right atrium; rv, right ventricle; san, sinoatrial node.](elife-56697-fig6){#fig6}

To assess the endogenous role of VR2 in the regulation of gene expression and AVCS function, we used CRISPR/Cas9-mediated genome editing to delete the 51 kb homologous region (−54 kb to −3 kb relative to *Tbx3*) from the murine genome (*Tbx3^∆VR2^*). Again, we validated the deletion by PCR and Sanger sequencing ([Figure 6---figure supplement 1A,C](#fig6s1){ref-type="fig"}). At E13.5, the observed distribution of *Tbx3^+/+^, Tbx3^∆VR2/+^* and *Tbx3^∆VR2/∆VR2^* embryos followed Mendelian ratios (data not shown). Postnatally, however, the observed number of *Tbx3^∆VR2/∆VR2^* pups was approximately half of the expected number (p=0.004, χ2 test; [Figure 6D](#fig6){ref-type="fig"}). We analyzed expression levels of *Tbx3* in microdissected AV junctions of E13.5 hearts and found an approximately 2.5-fold increase in expression in *Tbx3^∆VR2/∆VR2^* hearts compared to *Tbx3^+/+^* littermates (p=2\*10^−11^; n = 8 and n = 9, respectively; [Figure 6E](#fig6){ref-type="fig"}), respectively. *Tbx3^∆VR2/∆VR2^* hearts showed increased expression of *Hcn4* (p=0.04) and *Cacna1g* (p=0.004), ion channel-encoding genes involved in AVCS function, and decreased expression of *Scn5a* (p=0.02), the cardiac sodium channel Nav1.5-encoding gene involved in conduction, compared to hearts of wildtype littermates ([Figure 6F](#fig6){ref-type="fig"}). Expression levels of *Gja5* and *Gja1,* target genes of *Tbx3* in the AVCS and encoding the fast conducting gap junction proteins Cx40 and Cx43, respectively, were not affected ([Figure 6F](#fig6){ref-type="fig"}). To assess whether deletion of VR2 affects the expression of genes flanking *Tbx3,* we measured expression levels of *Tbx5*, *Rbm19* and *Med13l* and found that expression of these genes was unchanged ([Figure 6F](#fig6){ref-type="fig"}), suggesting VR2 only regulates *Tbx3* in the AVCS. *Tbx3* is also involved in the development of other tissues including the limbs, liver and lungs ([@bib22]; [@bib45]; [@bib46]). As the observed number of *Tbx3^∆VR2/∆VR2^* mice after birth was lower than expected, we asked whether *Tbx3* expression in these tissues is affected upon deletion of VR2, thereby potentially causing lethality. We measured *Tbx3* expression levels in sinoatrial nodes (SANs), forelimbs, liver and lungs of E13.5 embryos, and found increased expression only in the SAN (p=0.013). Expression in other tissues was not affected ([Figure 6F](#fig6){ref-type="fig"}). We next asked whether the upregulation of *Tbx3* in the embryonic AVCS is caused by increased expression in cells within its expression domain or by expansion of its expression domain in the heart. We performed in situ hybridization on E13.5 *Tbx3^+/+^* and *Tbx3^∆VR2/∆VR2^* hearts and observed no difference in expression pattern for *Tbx3* between *Tbx3^+/+^* and *Tbx3^∆VR2/∆VR2^* hearts ([Figure 6G](#fig6){ref-type="fig"}).

To assess the in vivo effects of deletion of VR2 on PR interval and QRS duration, we measured surface ECGs in *Tbx3^+/+^* and *Tbx3^∆VR2/∆VR2^* mice (n = 8 and n = 8, respectively). *Tbx3^∆VR2/∆VR2^* mice showed shortened PR intervals compared to *Tbx3^+/+^* mice (30.4 ms and 35.3 ms, respectively; p=0.025; [Figure 6H](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2F](#fig6s2){ref-type="fig"}). The QRS duration in *Tbx3^∆VR2/∆VR2^* mice was increased compared to wildtypes (15.1 ms and 11.7 ms, respectively; p=0.004; [Figure 6I](#fig6){ref-type="fig"}, [Figure 6---figure supplement 2F](#fig6s2){ref-type="fig"}). Recordings of ex vivo ECGs on these hearts under Langendorff perfusion revealed a similar effect on PR interval and QRS duration, suggesting the autonomic nervous system is not involved in changed parameters upon deletion of VR2 ([Figure 6---figure supplement 2G,H](#fig6s2){ref-type="fig"}).

Taken together, these results show that deletion of VR1 in mice does not affect expression levels or AVCS function. Deletion of VR2 affects *Tbx3* expression in the AVCS and causes misregulation of target genes and affected conduction parameters.

Discussion {#s3}
==========

Deciphering the mechanisms underlying gene regulation and the effects of trait-associated variation on these mechanisms is challenging for tissue types like the AVCS, which is small, heterogeneous and poorly available, and for which relevant model cells for functional and (epi)genomic experiments do not yet exist. Here, we functionally characterized two variant regions in the gene desert upstream of *TBX3* that have been associated with PR interval and QRS duration, parameters for cardiac conduction, in the human population. Both regions are located within genomic domains that recapitulate AVCS expression in vivo. They harbor multiple active regulatory elements as determined by STARR-seq and analysis of epigenetic data, the activity of a subset of which was found to be affected by the risk haplotype. Deletion of the orthologue of the distal region from the mouse genome did not affect *Tbx3* expression or AVCS function. Deletion of the proximal region increased *Tbx3* expression in the AVCS and affected both PR interval and QRS duration in vivo.

A large number of PR interval and QRS duration-associated variants has been identified within loci close to genes important for cardiac conduction system development and function ([@bib61]; [@bib74]; [@bib76]; [@bib81]; [@bib83]). Assigning function to these associations has been proven challenging. The vast majority of GWAS variation is located in non-coding genomic regions and therefore potentially affects the function of *cis-*REs, substantially impacting gene regulation and contributing to disease susceptibility ([@bib51]; [@bib71]). The identification of REs driving expression of genes active in the AVCS is hampered by the fact that the AVCS comprises only a small proportion of the heart. Consequently, the isolation of AVCS tissue for experimental procedures is challenging. eQTL analysis of associated variants is limited by the low number of available genotyped human AVCS samples, and AVCS-like cell lines for downstream functional testing of regulatory mechanisms are lacking. Using genome-wide murine AVCS-specific ATAC-seq and murine and human locus-wide functional enhancer screening using STARR-seq, we aimed to circumvent these issues and generate a means to identify REs potentially affected by GWAS variation.

GWAS typically identifies common variants, relatively frequently present in the human genome, and their effect size on the respective traits is usually small ([@bib49]; [@bib52]). Haploinsufficiency of *TBX3*, *TBX5* and other transcription factor-encoding genes causes congenital defects ([@bib9]; [@bib10]; [@bib72]) and is therefore not well tolerated, implying that even the modest effects of common variants on expression of such genes may have a relatively large effect on phenotypes. Furthermore, genes encoding developmental transcription factors are frequently under transcriptional control of multiple redundant REs ([@bib16]; [@bib54]; [@bib59]). The cardiac and limb expression of *Tbx3* involves multiple redundant or synergistically acting REs, which was previously shown by modified BAC and reporter transgenics ([@bib59]; [@bib82]). Our current findings further substantiate regulatory redundancy in vivo. Two different BACs harbor the regulatory information for reporter gene expression in the AVCS and other tissues expressing *Tbx3*, whereas deletion of VR1 did not affect gene expression or AVCS function ([@bib59]; [@bib82]). Combining this RE redundancy with the small effect size of associated variants, efforts to pinpoint individual causal variants in vivo or in modified (human) pluripotent stem cell-derived cardiac cell types will be challenging and with the currently available tools probably futile. Indeed, associations for many disease risk loci arise from multiple variants in LD that affect clusters of enhancers targeting the same gene ([@bib21]). Therefore, we set out to assess the effect of deletion of the entire variant regions within the *TBX3* locus rather than assessing the effect of individual SNPs, and found that the two *TBX3* risk loci harbor multiple active REs whose activity is affected by their respective risk alleles. Common genomic variation within these regions therefore probably affects the function of multiple redundant REs, rather than individual elements, that together orchestrate the complex regulation of *Tbx3* expression in the AVCS.

Despite the presence of four active REs within VR1, the activity of which is affected by PR and QRS duration associated variation, deletion of the VR1 orthologue from the murine genome did not lead to affected gene expression or AVCS function. Disease-causing non-coding variants in the human genome can affect RE activity and thereby gene expression by altering transcription factor binding ([@bib24]; [@bib51]; [@bib71]), resulting in GWAS association. Genomic deletion of the entire VR1 removes the potentially affected REs from the genome and disrupts the topology of the locus, which could be functionally buffered by redundancy within the locus ([@bib16]; [@bib44]; [@bib59]). Such redundancy is possibly not deployed in the case of only a variable nucleotide in an otherwise unaffected regulatory sequence (or genomic topology), providing a possible explanation for the absence of effect we observed in *Tbx3^∆VR1/∆VR1^* mice ([@bib16]; [@bib44]; [@bib59]).

Deletion of VR2 from the murine genome results in increased expression of *Tbx3,* and affected AVCS function. Regulation of the precise spatiotemporal activation of gene expression is orchestrated by various types of regulatory DNA elements including promoters, enhancers, silencers, insulators and other types of elements involved in conformation ([@bib32]; [@bib44]; [@bib50]). As we have previously identified an RE (Tbx3-eA) that activates gene expression in the AVCS ([@bib82]) that is located within VR2 ([@bib82]), the increased expression of *Tbx3* observed in *Tbx3^∆VR2/∆VR2^* hearts could be caused by a disruption of the fine balance between activating and repressive REs within VR2 that orchestrate the modulation of *Tbx3* regulation. Indeed, in the adult heart multiple regions within VR2 are marked by H3K27me3 (data not shown), a histone mark associated with transcriptional repression ([@bib29]; [@bib55]), suggesting VR2 potentially harbors multiple silencer elements.

The role of Tbx3 in conduction system function and development has been well demonstrated ([@bib7]; [@bib26]; [@bib35]; [@bib36]). Tbx3 has a large number of target genes enriched for ion handling protein-encoding genes ([@bib8]; [@bib26]; [@bib36]). As such, hundreds of genes that potentially influence the electrophysiological properties of the AVCS are likely to be deregulated in *Tbx3^∆VR2/∆VR2^.* Not only *Tbx3* insufficiency ([@bib7]; [@bib26]; [@bib36]) but also over-expression (this study, [@bib15]) can be detrimental, suggesting proper AVCS function depends on strictly balanced Tbx3 levels. The balance between Tbx3 (imposing a nodal gene program) and Tbx5 (imposing a fast-conductive gene program) was found to be important in the function and gene regulation of the VCS (i.e. AV bundle and branches) ([@bib15]). This balance model would predict conduction slowing when Tbx3 levels are increased. However, we observed shortened PR intervals indicative of faster AVCS conduction in *Tbx3^∆VR2/∆VR2^* mice (which have 2--3 fold increased *Tbx3* expression levels in AVCS), while *Tbx5* was not deregulated. This suggests that the Tbx3/Tbx5 balance model does not hold for the AV node. Several other transcription factors have been implicated in AVCS gene regulation, which together with Tbx3 and Tbx5 form a complex gene regulatory network that has not yet been fully elucidated ([@bib79]). Further studies are required to unravel the mechanisms through which *Tbx3* dose influences the AVCS gene regulatory network and PR interval or QRS duration.

A major limitation of massive parallel reporter assays like STARR-seq is that DNA fragments are tested for regulatory potential episomally and out of genomic context ([@bib3]), lacking the intricate relationship between DNA, histones and long range chromatin interactions ([@bib27]; [@bib38]). Intrinsic sequence activity or transcription factor binding to motifs within regions endogenously repressed or residing in closed chromatin might activate reporter gene expression when tested in episomal assays. This potentially yields multiple false positive sequences, that is transcriptionally active sequences not relevant for endogenous gene regulation ([@bib39]). Furthermore, we used the reporter vector described in [@bib3] to generate our libraries. A recent study from the same group showed that the bacterial plasmid origin-of-replication within this vector acts as a conflicting core-promoter, thereby causing confounding false-positives and --negatives ([@bib56]). In addition, the relatively high basal activity of the super core promoter (SCP1) in this vector potentially decreases the fold-change of signal to input ([@bib56]). As enhancer activity often depends on its ability to interact with the proper promoter ([@bib4]; [@bib86]), testing our libraries with the endogenous *Tbx3* promoter could yield more relevant RE candidates. The weak overlap of STARR-seq regions with EMERGE and AVCS-ATAC-seq regions illustrates that a subset of the STARR-seq-identified active regions might not be transcriptionally relevant for *Tbx3* expression in vivo. Indeed, the correlation is low between luciferase reporter activity and STARR-seq activity of candidate sequences from the murine genome selected based on either strong epigenomic hallmarks (EMERGE/ChIP-seq/ATAC-seq; high luciferase-/low STARR-seq activity) or strong STARR-seq signal (mSTARR_SG4; high STARR-seq-/low luciferase activity) ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Nevertheless, given the scarcity of alternative epigenomic datasets derived from human AVCS tissue, STARR-seq on the human *TBX3* locus provides a useful albeit somewhat more supportive tool to identify REs.

The lack of readily available AVCS cell lines prompted us to transfect our STARR-seq libraries in COS-7 cells, a monkey kidney-derived fibroblast cell line. Although seemingly irrelevant for assessing regulatory activity of potential AVCS-involved REs, the high transfection efficiency of COS-7 cells allowed us to screen multiple libraries on a large scale and acquire sufficient coverage. The inactivity of a cardiac-specific gene program in COS-7 cells furthermore allowed us to specifically assess the response of genomic fragments to the cotransfected SG4- and Tcf-factors. Our observation that binding motifs for these factors are specifically enriched in AVCS cardiomyocytes, indicated these factors may be involved in regulation of the AVCS gene program. Motif enrichment in AVCS-specific accessible regions was performed by matching AVCS-specific accessible regions to motifs present in the HOMER database. Such databases have their limitations, as they are incomplete and possibly inaccurate as they derive their input from experimental procedures that are condition- and cell type-dependent. Nevertheless, the observed enrichment supported previous studies implicating Bmp-signalling (Smads), Gata4/6 and Wnt-signalling (Tcf) in AVCS patterning ([@bib75]; [@bib28]).

Several of the tested risk alleles (e.g. hRE8, hRE9, hRE18) showed a discordant direction of effect between basal activity in COS-7/HL-1 and SG4-/Wnt-stimulated activity. This observation suggests that potentially multiple factors act on these variant REs, with SG4- or Tcf factors counteracting the effect of regulatory networks active in COS-7 or HL-1 cells. Although we could not identify specific TF binding motifs affected by the respective SNPs in these REs, studying TF occupancy in more detail specifically in AVCS cells could elaborate on the precise mechanisms through which these variant REs act. By focusing on SG4- and Wnt-responsive REs, we potentially overlook a proportion of relevant sequences involved in the regulation of *Tbx3* expression, as multiple other factors are involved in AVCS development ([@bib11]; [@bib60]; [@bib79]). Recent and ongoing advantages in the generation of (sinoatrial/atrioventricular) nodal-like cells derived from human pluripotent stem cells ([@bib12]; [@bib40]; [@bib62]; [@bib67]) will provide a promising tool to study the regulation of genes involved in AVCS development and the function of candidate REs in a considerably more relevant cell type.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                        Designation                           Source or reference              Identifiers                                                  Additional\
  (species) or resource                                                                                                                                                    information
  ------------------------------------ ------------------------------------- -------------------------------- ------------------------------------------------------------ -----------------------------------------------------------------------------------------------
  Cell line (*Chlorocebus aethiops*)   COS-7                                 ATCC                             RRID:[CVCL_0224](https://scicrunch.org/resolver/CVCL_0224)   Fibroblast cell line

  Cell line (*Mus musculus*)           HL-1                                  William C. Claycomb ([@bib20])   RRID:[CVCL_0303](https://scicrunch.org/resolver/CVCL_0303)   Cardiomyocyte cell line

  Genetic reagent (*Mus musculus*)     *Tbx3^∆VR1/+;^ Tbx3^∆VR1/∆VR1^*       This paper                                                                                    See Materials and methods, section 'TALEN/CRISPR/Cas9-mediated genome editing of\
                                                                                                                                                                           VR1 and VR2'

  Genetic reagent (*Mus musculus*)     *Tbx3^∆VR2/+;^ Tbx3^∆VR2/∆VR2^*       This paper                                                                                    See Materials and methods, section 'TALEN/CRISPR/Cas9-mediated genome editing of VR1 and VR2'

  Genetic reagent (*Mus musculus*)     *Tbx^459M16-GFP/+^*                   This paper                                                                                    See Materials and methods, section 'BAC modification and immunohistochemistry'

  Recombinant DNA reagent              pSTARR-seq_human                      [@bib3]                          Addgene;\                                                    
                                                                                                              Plasmid \#71509                                              

  Commercial assay or kit              Nextera DNA library\                  Illumina                         FC-121--1030                                                 
                                       prep kit                                                                                                                            

  Commercial assay or kit              NEBNext DNA Library Preparation Kit   New England Biolabs              NEB E6000S                                                   

  Commercial assay or kit              NEBNext Multiplex\                    New England Biolabs              NEB E7335S                                                   
                                       Oligos for Illumina                                                                                                                 

  Software, algorithm                  EMERGE                                [@bib77]                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SNP plotting and human Hi-C analysis {#s4-1}
------------------------------------

Genome-wide significant SNPs associated with PR interval and QRS duration were extracted from [@bib76] and [@bib81]. Within genomic loci marked by genome-wide significant SNPs (p\<5\*10^−8^), SNPs with a p-value\<0.05 were included according to the relevance of sub-threshold SNPs described in ref ([@bib85]). We also included common variants in high linkage disequilibrium (LD; r^2^ \>0.5) with the top SNPs for both variant regions in our analysis ([@bib48]). SNPs were plotted on the human genome (hg19) using the UCSC Genome Browser ([@bib41]). Hi-C data of the human *TBX3* locus and resulting TAD boundaries were obtained from GM12878 human lymphoblastoid cells ([@bib66]).

ATAC-seq on Tbx3+ AVCS cardiomyocytes {#s4-2}
-------------------------------------

ATAC-seq on FACS-purified E12.5-E14.5 *Tbx3^Venus/+^* AVJs ([@bib79]) was performed and analyzed as described in [@bib14]. In short, *Tbx3*^Venus/+^ hearts were dissected from embryonic day (E) 12.5-E14.5 embryos and enriched for AV conduction system tissues by microdissection. Single-cell suspensions were obtained using 0.05% Trypsin/EDTA (ThermoFisher Scientific, 25300--054). Cells were sorted on a FacsAria flow cytometer (BD biosciences) and gated to exclude debris and cell clumps, and sorted for Venus^+^ cells. Approximately 75.000 Venus^+^ cells were collected and used as input for ATAC-sequencing, which was performed as previously described ([@bib14]). The library was sequenced (paired-end 125 bp) and data was collected on a HiSeq2500. ATAC-seq data is deposited in the GEO database under accession number GSE121464.

STARR-seq library preparation {#s4-3}
-----------------------------

STARR-seq was performed as described previously ([@bib3]). In short, BACs spanning the entire human and murine *TBX3* locus were used to generate human and murine STARR-seq libraries. BACs were equimolarly pooled, approximately 15 µg of pooled BAC DNA was sheared by sonication (Amp 20%, 2 × 15 s) and fragments of approximately 500--1000 bp were selected by gel extraction followed by cleanup using the Qiaquick Gel extraction kit (Qiagen; 28704). 1.5 µg of size-selected DNA fragments was used as input for library preparation using the NEBNext DNA Library Preparation Kit (NEB; E6000S) and NEBNext Multiplex Oligos for Illumina (NEB E7335S) according to manufacturer's protocol. Recombination of adapter-ligated DNA fragments, transformation and library DNA isolation was performed as described ([@bib3]).

STARR-seq transfection {#s4-4}
----------------------

15\*10^6^ COS-7 cells were cultured in DMEM (ThermoFisher Scientific; 31966--021) supplemented with 10% FBS (ThermoFisher Scientific; 10270--106) and 1% Pen/Strep (ThermoFischer Scientific; 15070--063). Cells were transfected with 150 µg library DNA and 75 µg of pcDNA (control), SG4 (15 µg Smad1, 15 µg Smad4, 30 µg Alk3 and 15 µg Gata4 expression vectors) or Wnt (15 µg Tcf4 expression vector, 60 µg pcDNA, and 0.4M LiCl) using Polyethylenimine 25 kDa (PEI; Sigma-Aldrich; 408727) in a ratio of 1:3 (DNA:PEI). Medium was refreshed 6 hr after transfection. 48 hr after transfection, total RNA was isolated using the Qiagen RNeasy maxi prep kit (Qiagen; 75162). polyA+ RNA was isolated using Dynabeads Oligo-dT~25~ (ThermoFisher Scientific; 61002) and treated with Ambion turboDNase (ThermoFisher Scientifc; AM2238) for 30 min at a maximum concentration of 150 ng/µl. RNA was purified using the Qiagen RNeasy MinElute kit (Qiagen; 74204). First-strand cDNA synthesis and library preparation was performed as described ([@bib3]). Library quality and concentration were assessed by Bioanalyzer (Agilent) and KAPA Library Quantification Kit (KAPA Biosystems; KK4824). Libraries were pooled equimolarly and sequenced on an Illumina MiSeq (PE150).

STARR-seq data analysis {#s4-5}
-----------------------

Paired-end sequence reads were mapped to mm9 (mSTARR) or hg19 (hSTARR) using BWA ([@bib43]). For visualization purposes, bam files were converted to bigwig files using bamCoverage ([@bib64]) and visualized using the UCSC genome browser ([@bib41]). We compared bam files of m/hSTARR_SG4/Wnt to m/hSTARR_control using bamCompare ([@bib64]) with bin sizes of 50 bases to compute the log2 of the number of reads ratio. Bins were filtered to exclude regions with a read count \<75. Flanking bins were merged using mergeBED (overlaps on either strand; maximum distance between features: 0) ([@bib63]). Merged bins with a log2 fold change of \>0.585 (fold change \>1.5) were included for further analysis. For overlap analysis, bed files were intersected using BEDTools ([@bib63]) with a minimum interval overlap of 50 bp.

EMERGE enhancer selection {#s4-6}
-------------------------

Putative mouse cardiac enhancers were predicted by EMERGE ([@bib77]) using a total of 116 selected functional genomic datasets. These included ChIP-seq data of enhancer-associated histone modification marks and transcription factor binding sites, and chromatin accessibility data as assessed by DNAseI-hypersensitivity and ATAC-seq, derived predominantly from cardiac cells. By assigning weight to all selected datasets through a logistic regression modeling approach (described in [@bib77]) using validated heart enhancers as training set, a genome-wide cardiac enhancer prediction track was generated. The same exercise was performed for the human genome, using a total of 70 selected functional genomic datasets. An overview of the datasets used of mouse and human EMERGE enhancer prediction is provided in [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Tables 10, 11.

ATAC-seq and H/mSTARR regions motif analysis {#s4-7}
--------------------------------------------

The ATAC-seq dataset on FACS-purified E12.5-E14.5 *Tbx3^Venus/+^* AVJs was utilized to identify accessible regions within the *Tbx3* locus. As genome-wide peak-calling algorithms did not fully call all peaks within the *Tbx3/Tbx5* locus, even with less stringent parameters, we used a local, locus-specific threshold value for the selection of peaks. The entire sequence surpassing the threshold was included and considered as potential RE. A similar approach was used to select ventricular ATAC-seq regions ([@bib78]), and a random selection of 67 regions from this set and the 67 accessible AVJ regions were used as input for the HOMER motif analysis tool ([@bib33]) to identify AVCS-specific enriched sequence motifs within the *Tbx3* locus.

Murine/human STARR-seq regions with fold change of stimulation over control of \>1.5 (see: *STARR-seq data analysis*) were used as input for the HOMER motif analysis tool ([@bib33]). Potential enrichment against genome background was checked for all known motifs in the JASPAR database ([@bib25]). To allow for comparison of motif enrichment between different datasets, we used 150 randomly selected active regions for hSTARR_SG4 and hSTARR_Wnt, and 181 randomly selected active regions for mSTARR_SG4 and mSTARR_Wnt as input. Input regions were defined as the complete genomic region surpassing the \>1.5 fold change threshold for activation over control.

Cloning of RE candidates {#s4-8}
------------------------

Murine and human regions selected based on either STARR-seq activity or EMERGE/ATAC-seq prediction for validation were amplified from respective BAC DNA (used for STARR-seq library preparation) in which they reside. Major and minor haplotypes of identified RE candidates were amplified from human DNA from individuals within the CONCOR-genes database. PCR amplification of RE sequences was performed using Q5 Hot Start High-Fidelity DNA Polymerase (NEB; M0493S). Primer sequences are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Tables 7-9. Amplified sequences were ligated in the *XcmI* site of a modified pGL2-SV40 vector (Promega) using T4 DNA Ligase (ThermoFisher Scientific; 15224--090). After transformation, plasmid DNA was isolated using the PureLink HiPure Plasmid Midiprep kit (ThermoFisher Scientific; K210005) and purified by phenol/chloroform extraction.

Cell culture {#s4-9}
------------

HL-1 cells (RRID:[CVCL_0303](https://scicrunch.org/resolver/CVCL_0303); 2.5\*10^6^ cells/plate) were grown in 12-well plates in Claycomb medium (Sigma-Aldrich, 51800C) supplemented with chemically defined HL-1 FBS substitute (Lonza, 77227), Glutamax (ThermoFisher Scientific, 35050--061) and Pen/Strep (ThermoFisher Scientific, 15070--063). COS-7 cells (RRID:[CVCL_0224](https://scicrunch.org/resolver/CVCL_0224); 1.5\*10^6^ cells/plate) were grown in 12-well plates in DMEM (ThermoFisher Scientific, 31966--021) supplemented with 10% FBS (ThermoFisher Scientific, 10270--106) and Pen/Strep (ThermoFisher Scientific, 15070--063). Both HL-1 and COS-7 cell lines were routinely tested negative for mycoplasma contamination. HL-1 cells and COS-7 cell lines were easily distinguished based on cellular morphology and contractility (HL-1). Neither HL-1 or COS-7 is found in the database of commonly misidentified cell lines that is maintained by the International Cell Line Authentication Committee.

Transient transfection and luciferase assays {#s4-10}
--------------------------------------------

HL-1 cells were transfected with plasmid DNA using Lipofectamine 3000 (ThermoFisher Scientific, L3000-015). 1 µg plasmid DNA was transfected using 4 µL P3000 reagent and 3 µL Lipofectamine. COS-7 cells were transfected using Polyethylenimine 25 kDa (PEI; Sigma-Aldrich; 408727) at a 1:3 ratio (DNA:PEI). 1 µg of reporter plasmid DNA was transfected with either 500 ng of pcDNA3.1(+) (ThermoFisher Scientific, V790-20) as control, or 100 ng Smad1, 100 ng Smad4, 200 ng Alk3 and 100 ng Gata4 expression vectors (SG4) and 100 ng Tcf4, 400 ng pcDNA, and 0.4M LiCl (Wnt). Medium was refreshed 6 hr after transfection. Cells were lysed 48 hr after transfection using Renilla luciferase assay lysis buffer (Promega, E291A-C). Luciferase activity measurements were performed in duplo using a GloMax Explorer (Promega, GM3500) with 100 ul D-Luciferin (p.j.k., 102111). Measurements were performed by a 1 s delay and 5 s of measurement per sample.

Analysis of disrupted/de novo created TF binding motifs in variant REs {#s4-11}
----------------------------------------------------------------------

Of the variant RE candidates of which the risk allele affected luciferase activity, we took the variant nucleotide and 10 nucleotides both up- and downstream. These 21 bp sequences were used as input for transcription factor binding motif recognition in JASPAR ([@bib25]) using default settings.

BAC modification and immunohistochemistry {#s4-12}
-----------------------------------------

The modification and analysis of BACs RP24-89K7-GFP, RP23-143N21-GFP and RP23-366H17-GFP has been previously described ([@bib36]),([@bib82]). BAC RP24-459M16 was obtained from a C57BL/6J mouse BAC library (CHORI, BACPAC Resources) and modified to generate 459M16-GFP. To this end, a GFP reporter gene cassette coupled to the minimal heat shock promoter 68 (hsp68-GFP) was inserted at 81 kb from the 5'-end of BAC 459M16 following the two-step BAC modification protocol as described in [@bib30]. Modified 459M16-GFP DNA was purified using the Nucleobond PC20 kit (Machery Nagel) and injected in pronuclei of FVB/N mice. Microinjected zygotes were implanted in pseudo-pregnant females (timepoint E0.5) and embryos were isolated at E13.5. GFP^+^ embryos were fixed in 4% paraformaldehyde in PBS for 4 hr and processed for immunohistochemistry, as described in [@bib82]. Three independent GFP^+^ founders were analysed for GFP expression.

TALEN/CRISPR/Cas9-mediated genome editing of VR1 and VR2 {#s4-13}
--------------------------------------------------------

For the deletion of VR1 from the mouse genome (*Tbx3*^∆VR1^), two genomic sites flanking were targeted by TALEN. TALEN target sequences were designed with TALENT2.0 (<https://tale-nt.cac.cornell.edu/>) and assembled according to the Golden Gate cloning protocol ([@bib18]). Genomic coordinates and RVD sequences of TALEN target sites are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 4 ([@bib17]).

Assembled RVDs were cloned in the pC-GoldyTALEN and RCIscript-GoldyTALEN ([@bib17]) destination vector to generate mRNA expression plasmids. TALEN mRNA was in vitro transcribed by linearization of the expression plasmid with *SacI* at 37°C for 3 hr, followed by transcription of the linearized DNA using the T7 mMessage Machine kit (ThermoFisher Scientific; AM1344). 20 ng/µl of TALEN mRNA was injected in the cytoplasm of one-cell embryos of FVB/N mice. Positive founders were identified by PCR with primers flanking the 69 kb deletion and subsequent Sanger sequencing. The genomic deletion in positive founders was backcrossed for at least two generations with wildtype FVB/N mice before further experiments.

To delete VR2 from the mouse genome (*Tbx3*^∆VR2^), oligonucleotides for the generation of two single guide RNAs (sgRNAs) targeting two genomic sites flanking VR2 in the mouse genome were designed using the online tool ZiFit Targeter ([@bib70]). Target site sequences are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 5. sgRNA oligonucleotides were ligated into *BsaI*-digested pDR274 using T4 DNA Ligase (Invitrogen). sgRNA (pDR274) and Cas9 (MLM3613) expression vectors were linearized with *DraI* (NEB, R0129S) and *PmeI* (NEB, R0560S), respectively. sgRNA and Cas9 in vitro transcription was performed using the MEGAshort T7 kit (Life Technologies, AM1354) and mMessage mMachine T7 Ultra kit (Life Technologies, AM1345), respectively, followed by purification using the MEGAclear kit (Life Technologies, AM1908). 10 ng/µl sgRNA and 25 ng/µl Cas9 mRNA was micro-injected into the cytoplasm of one-cell embryos of FVB/N mice. The genomic deletion in positive founders was backcrossed for at least two generations with wildtype FVB/N mice before further experiments.

In situ hybridization {#s4-14}
---------------------

E13.5 embryos were isolated in ice cold PBS and fixated overnight in 4% paraformaldehyde in PBS, dehydrated in a graded ethanol series, embedded in paraplast and sectioned at 10 µm. Non-radioactive in situ hybridization on sections was performed as previously described ([@bib53]) using mRNA probes for the detection of *Tbx3, Tbx5* and *Hcn4.* Stained sections were examined with a Zeiss Axiophot microscope and photographed with a Leica DFC320 Digital Camera.

Quantitative expression analysis {#s4-15}
--------------------------------

For the quantification of expression levels, E13.5 embryos from *Tbx3^+/+^, Tbx3^VR1/+^, Tbx3^VR2/+^, Tbx3^VR1/VR1^* and *Tbx3^VR2/VR2^* were isolated in ice cold PBS and liver, limbs, lungs, AVJs and SANs were isolated by microdissection. Total RNA was isolated by the ReliaPrep RNA Tissue Miniprep System (Promega; Z6112) according to manufacturer's protocol. First-strand cDNA was synthesized with 500 ng total RNA as input using SuperScript II Reverse Transcriptase (ThermoFischer Scientific; 18064022). Quantitative real-timePCR was performed in technical duplicates using the Roche LightCycler 480 system. The oligonucleotide sequences for the amplification of the different amplicons are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}-Supplementary Table 6. The relative start concentration was calculated as described in [@bib69]. Expression values of the different amplicons were normalized to the geomean of *Hprt* and *Eef2* expression (liver, limbs, lungs), *Tbx2* expression (AVJ) and *Isl1* expression (SAN). Expression values in tissues of *Tbx3^VR1/+^, Tbx3^VR2/+^, Tbx3^VR1/VR1^* and *Tbx3^VR2/VR2^* mice were compared to those of wild-type littermates (*Tbx3^+/+^*).

Recording of in vivo and ex vivo electrocardiograms {#s4-16}
---------------------------------------------------

*Tbx3*^+/+^, *Tbx3*^∆VR1/∆VR1^ *and Tbx3*^∆VR2/∆VR2^ mice (male, 2--4 months old) were anesthetized with 4% Isoflurane (Pharmachemie B.V.) and maintained at 1.5--2.0%. Electrodes were placed at the right (R) and left (L) armpit and the left groin (F) and an electrocardiogram (ECG) was recorded (PowerLab 26T; AD-Instruments, Colorado Springs, CO, USA) for a period of 5 min. ECG parameters were determined in Lead II (L-R) based on the last 30 s of the recording.

To record ECGs ex vivo the adult mice were sacrificed by CO~2~ (1 L/min inflow) and cervical dislocation. The heart was rapidly excised, cannulated, mounted on a Langendorff perfusion set-up as described previously ([@bib13]). Neonatal mice (ND0-1) were sacrificed by 4% Isoflurane and cervical dislocation. Hearts were isolated and superfused with HEPES-buffered Tyrode's solution (containing in mmol/L: 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1.0 MgCl2, 5.5 glucose and 5.0 HEPES) at a temperature of 36 ± 0.2°C; pH was set to 7.4 with NaOH. During perfusion the heart was submerged and electrodes were placed at the right (R) and left (L) side of the base of the heart and at the left side of the apex (F) at a 5 mm distance. Lead II was used to determine ECG parameters. ECG parameters both in vivo and ex vivo for *Tbx3*^∆VR1/∆VR1^ *and Tbx3*^∆VR2/∆VR2^ mice were compared to those of wild-type littermates (*Tbx3*^+/+^).
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###### Supplementary Tables 1---11.

Supplementary Table 1. Transcription factor binding motif enrichment in genomic regions accessible in E14.5 atrioventricular junctions. Transcription factor binding motif enrichment in 67 genomic regions accessible in E14.5 atrioventricular junctions (AVJ) or E14.5 ventricles. Enrichment was compared to enrichment in a number of random control sequences. Enrichment is depicted as total number of regions with the motif and the percentage of the total number of tested regions. P-values depict statistical significance of enrichment. Supplementary Table 2. Transcription factor binding motif enrichment in active STARR-regions. Transcription factor binding motif enrichment in genomic regions within both mouse (A) and human (B) *TBX3* locus that respond to Smad/Gata (SG4) or Tcf (Wnt) factors as demonstrated by STARR-seq. Enrichment of binding motifs for Smad/Gata- and Tcf-factors is depicted. Enrichment was compared to enrichment in a number of random control sequences. Enrichment is depicted as total number of regions with the motif and the percentage of the total number of tested regions. P-values depict statistical significance of enrichment. Supplementary Table 3. Murine RE candidates within VR1 and VR2. Murine RE candidates selected based on accessible chromatin in AV junction cardiomyocytes (ATAC_AVJ), EMERGE prediction, or mSTARR_SG4/Wnt activity. Overlap is depicted of candidate regions with ChIP-seq peaks from publicly available datasets for Gata4 (differentiated cardiomyocytes) ([@bib47]), Hand2 (E10.5 heart) ([@bib42]) and H3K27ac (E11.5 heart) ([@bib58]). Supplementary Table 4. Human RE candidates within VR1 and VR2. Human RE candidates selected based on mouse RE homology (mm9 liftover), EMERGE prediction, or hSTARR_SG4/Wnt activity. Regions overlapping GWAS SNPs (SNP id, trait association and respective p-value are listed) were selected for further analysis. Supplementary Table 5. TALEN/CRISPR target sequences for deletion of VR1 and VR2 from the murine genome Supplementary Table 6. qPCR primer sequences Supplementary Table 7. Overview of BACs used for the generation of STARR-seq libraries Supplementary Table 8. Primer sequences for the amplification of active STARR-seq regions for validation by luciferase reporter assay Supplementary Table 9. Primer sequences for the amplification of RE candidate fragments Supplementary Table 10. Mouse functional genomic datasets included in merge as possible predictors Supplementary Table 11. Human functional genomic datasets included in merge as possible predictors.
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Sequencing data have been deposited in GEO under accession codes GSE121464 and GSE145257.

The following dataset was generated:

van WeerdJHvan DuijvenbodenKChristoffelsVM2020STARR-seq of human and mouse Tbx3 locusNCBI Gene Expression OmnibusGSE125257

The following previously published dataset was used:

MohanRAvan WeerdJHvan DuijvenbodenKChristoffelsVM2019Tbx3 governs a transcriptional program to maintain atrioventricular conduction system form and function \[ATAC-seq\]NCBI Gene Expression OmnibusGSE121464
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

The manuscript presents an integrated approach for investigating genetic variation identified by GWAS, traveling from human genetics through informatics and genomic analysis to validation in a mouse model. This approach may be broadly applicable. Equally interesting are the specific findings concerning gene regulation at the TBX3 locus, including the identification of several enhancers, at least one of which is shown to be required in vivo.

**Decision letter after peer review:**

Thank you for submitting your article \"Trait-associated noncoding variant regions affect *TBX3* regulation and cardiac conduction\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Ivan P Moskowitz as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Didier Stainier as the Senior Editor The following individual involved in review of your submission has agreed to reveal their identity: Tony Firulli (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

Hendrik van Weerd et. al is a very good manuscript detailing a functional genomics approach to understanding regulation of the TBX3 gene and investigating GWAS variants for cardiac rhythm traits at the TBX3 locus. The paper includes an interrogation of common non-coding genomic variants upstream and in cis with the T-box transcription factor TBX3 associated with changes in cardiac conduction velocity.

The paper excels in several ways. First, it provides a comprehensive approach to travel from trait-associated variants to functional investigation of the gene regulatory consequences of specific variants, attempting to link them to phenotypic consequences. Second, it advances our understanding of the cis-regulatory landscape at TBX3 and reveals a likely molecular mechanism for GWAS signals at the TBX3 locus -- specifically, variation of cis-regulatory element function affecting TBX3 expression in conduction tissues. Third, it considers and tackles some basic difficulties in understanding cardiac conduction system GWAS -- the lack of human expression data for cardiac conduction tissues and therefore the lack of eQTL data for such tissues implicated in cardiac rhythm control. The mouse -- human pipeline presented provides a potential roadmap for future studies in the CCS or in other tissues that lack human expression data.

Revisions:

The specific comments are meant to clarify the manuscript. The generation of new data is not necessary for the revision. The following issues should to be clarified in a revision manuscript, either by analysis of current data or by clarification of the text and/or figures:

1\) In-vivo functional analysis is not of SNPs themselves but of a much larger enhancer deletion. This caveat should be discussed with regards to the molecular mechanism underlying the GWAS association caused by SNPs.

2\) Some of the observed molecular and functional effects of SNPs or enhancer knockouts are unexpected and are left without a mechanistic explanation. For example, analysis of the in-vivo effects of removal of VR2 generated results for Tbx3 expression and for functional conduction measures that are opposite of expectations. Tbx3, a repressor of fast conduction channels, was upregulated in conduction tissues, generating the expectation that conduction would be slowed in affected regions. However, a decreased PR interval, indicative of more rapid conduction speed, was observed. Can the authors explain why this is the case? At the very least the authors should discuss the unexpected nature of this observation and offer a plausible explanation.

3\) The Motif data presented in a few of the figures may not be accurate. It is clear that the VR2 is functional and published DNA occupancy data shows associated DNA binding from defined TFs within the RE\'s; however, the sequence consensus shown for the bHLH factors (sans MyoD) do not contain E-boxes, *SOX9* and SMAD Motifs reported also appear non-canonical. Discussing this at some level is warranted.

4\) ATAC-seq was performed in embryonic hearts and traits were from adult humans. This comparison may underestimate the overlap were ATAC to be done on adult AVC cells. This caveat should be discussed.

5\) The authors interrogated the human TBX3 locus for TAD structure and the location of SNPs associated with conduction traits; they identified candidate REs in the AVC by performing AVC ATAC-seq, which should provide an excellent resource for the field.

How were the 67 candidate REs at the Tbx3 locus defined relative to the entire dataset?

How specific are the identified elements for the AVC as opposed to non-AVC myocardium?

The authors show but do not discuss the comparison between the AVC versus ventricular ATAC across the Tbx3 locus. How many are AVC-specific? It looks like many are shared.

Did the author\'s attempt a differential ATAC analysis across the locus?

6\) The STARR analysis was performed in COS cells to identify regions that activate transcription based on specific TFs previously defined as important for AVC gene expression. As the authors indicate, there is no AVC cell line, requiring use of an unrelated line. None-the-less, the use of COS cells is a significant caveat, and should be discussed clearly in the Discussion. The TF enrichment in this context is a therefore a self-fulfilling prophecy.

The number of human and mouse STARR identified candidates, as well as their overlap, should be described up front.

7\) The description of mouse/human homology for VR1 and VR2 should be described in more detail.

8\) RE candidate selection is described in Fg3a using a hierarchical approach in schematic form.

It should be possible to use the actual locus, display the individual datasets, and overlay them to present a more accurate description of the chosen REs at the locus.

Figure 3B appears to display data already published. Were any other candidates tested in-vivo?

9\) Several of the candidate risk alleles, examined in luciferase activity in Figure 4C and d, show discordant effects on basal activity and TF-stimulated activity. This should be described and considered. Do the variants alter TF binding sites of known activator or repressor TFs that would help explain this discordance? Do any of the analyzed variants alter TF binding sites of the TF analyzed, which may explain their altered regulatory response to TF expression?

10\) In Figure 6, the schematic shows the location of the TALEN cuts. The authors should delineate VR1 and VR2, as in Figure 5.

11\) Figure 1C do the authors have insight as to why the Motif consensus for HAND2, TCF3, and TCF4 do not contain a clear E-box motif such as shown for MyoD? The *SOX9* Motif also seems out of place with the canonical consensus: CCTTGAG. SMAD 3&4 likewise are reported to bind CAGAC, CAGCC as well as the 5-bp consensus sequence GGC(GC)\|(CG). What is shown in the motif is very different and some discussion of this is warranted there is not confidence that the aforementioned transcription factors would bind these sequences robustly. There is simply low confidence that the algorithm is pulling accurate motif data and the authors should try to address this in the text.

12\) Figure 2 same issue with consensus data in 2G (note the motif name and the motif do not line up correctly).

13\) Figure 3 some clarity in the narration would be helpful. Paragraph one of subsection "Identification of variant REs within VR1 and VR2" discuss 9 candidate REs in VR1 and 13 in VR2. Are these regions supposed to be identifiable in Figure 3A (as is the assumption)? The figure shows 6 candidate REs which resolve to 3 with SNP overlaps comparing the figure to the narration is confusing.

14\) Figure 6C shows only Tbx3 expression Tbx5 and Med13l expression narrated as being in Figure 6C. Panel G would benefit from slightly enlarged images.

15\) The criteria and datasets used to define the EMERGE regions is not found in this paper nor is there any citation listing where these regions came from. Please clarify.

16\) What was the criteria used to identify the 9 and 13 (as listed in the text) candidate regulatory elements in VR1/2? Supplementary Table 4 lists only 20 candidate regulatory elements (7 and 13). What happened to hRE1 and hRE2 to exclude them from downstream analysis and inclusion in the table? Were other sites excluded as well? It is also unclear from Figures 2H-K and Figure 3A, and Supplementary Tables 3 and 4 what was used to define the candidate regulatory elements examined in greater detail in Figures 4, Figure 3---figure supplement 1 and Figure 4---figure supplement 1. For example, hRE13 was not examined in Figures 4C/D or Figure 4---figure supplement 1. Overall, I really like the multi-factor approach to defining candidates; however, the key filtering steps taken to get the final list of candidates needs to be more clearly defined.
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Author response

> Revisions:
>
> The specific comments are meant to clarify the manuscript. The generation of new data is not necessary for the revision. The following issues should to be clarified in a revision manuscript, either by analysis of current data or by clarification of the text and/or figures:
>
> 1\) In-vivo functional analysis is not of SNPs themselves but of a much larger enhancer deletion. This caveat should be discussed with regards to the molecular mechanism underlying the GWAS association caused by SNPs.

We agree and have elaborated in the Discussion: "Our current findings further substantiate regulatory redundancy in vivo. \[...\] Therefore, we set out to assess the effect of deletion of the entire variant regions within the TBX3 locus rather than assessing the effect of individual SNPs, and found that the two TBX3 risk loci harbor multiple active REs whose activity is affected by their respective risk alleles."

> 2\) Some of the observed molecular and functional effects of SNPs or enhancer knockouts are unexpected and are left without a mechanistic explanation. For example, analysis of the in-vivo effects of removal of VR2 generated results for Tbx3 expression and for functional conduction measures that are opposite of expectations. Tbx3, a repressor of fast conduction channels, was upregulated in conduction tissues, generating the expectation that conduction would be slowed in affected regions. However, a decreased PR interval, indicative of more rapid conduction speed, was observed. Can the authors explain why this is the case? At the very least the authors should discuss the unexpected nature of this observation and offer a plausible explanation.

We agree the result was unexpected. Reduction of Tbx3 also results in PR shortening (Frank et al., 2012), suggesting that both more and less than normal Tbx3 causes apparent faster conduction through the AV conduction system. While several channels and gap junction subunits that are also targets of Tbx3 have been indicated to dose dependently contribute to conduction (Scn5a/Nav1.5, Gja5/Cx40 etc.), many more genes will be deregulated in the mutant AV conduction system, leading to changes in a complex genetic network with currently unpredictable output. We have discussed this in the Discussion section, also referring to recent work from the Moskowitz lab regarding the interplay between Tbx5 and Tbx3 in the AV bundle.

"Not only Tbx3 insufficiency (Bakker et al., 2008; Frank et al., 2011; Horsthuis et al., 2009) but also over-expression (this study, Burnicka-Turek et al., 2020) can be detrimental, suggesting proper AVCS function depends on strictly balanced Tbx3 levels. \[...\] Further studies are required to unravel the mechanisms through which *Tbx3* dose influences the AVCS gene regulatory network and PR interval or QRS duration."

> 3\) The Motif data presented in a few of the figures may not be accurate. It is clear that the VR2 is functional and published DNA occupancy data shows associated DNA binding from defined TFs within the RE\'s; however, the sequence consensus shown for the bHLH factors (sans MyoD) do not contain E-boxes, SOX9 and SMAD Motifs reported also appear non-canonical. Discussing this at some level is warranted.

We agree with the reviewer, and have specified interpretations of the Motif analysis. The confidence of such analyses depends on the quality of motifs within the database, which are experimentally derived from different experiments, in various cell types or developmental stages. As such, scanning sequences for motif enrichment using HOMER or other large scale analysis tools should be interpreted with this in mind. Nevertheless, we used the analysis to obtain a global impression of the factors that could be involved in AVCS Tbx3 regulation, while being aware that the output list is far from comprehensive. We have toned down statements regarding the conclusion of this analysis in the Results and Discussion section, and have specified in the Discussion that we used this analysis mainly to obtain an impression of involved factors, and have discussed the caveats of this analysis. Furthermore, we have removed the motif logos from Figure 1C.

> 4\) ATAC-seq was performed in embryonic hearts and traits were from adult humans. This comparison may underestimate the overlap were ATAC to be done on adult AVC cells. This caveat should be discussed.

We agree with the reviewer that we might underestimate the overlap of GWAS-SNPs with potential REs, as we do not include adult AVC ATAC-seq in our analysis. However, we assume that a large proportion of the potential regulatory elements accessible in adult tissues are also accessible at developmental stages. The embryonic ATAC-seq data is furthermore only one of the filtering steps for selecting candidate REs, as we also use mouse and human STARR-seq, and mouse and human EMERGE prediction, which is based on multiple datasets including some derived from adult mouse tissues and human tissues. Nevertheless, including ATAC-seq data derived from adult Tbx3+ hearts could yield additional regulatory elements that are potentially missed in this configuration and we have added this limitation to the Conclusion.

> 5\) The authors interrogated the human TBX3 locus for TAD structure and the location of SNPs associated with conduction traits; they identified candidate REs in the AVC by performing AVC ATAC-seq, which should provide an excellent resource for the field.
>
> How were the 67 candidate REs at the Tbx3 locus defined relative to the entire dataset?
>
> How specific are the identified elements for the AVC as opposed to non-AVC myocardium?
>
> The authors show but do not discuss the comparison between the AVC versus ventricular ATAC across the Tbx3 locus. How many are AVC-specific? It looks like many are shared.
>
> Did the author\'s attempt a differential ATAC analysis across the locus?

To increase specificity and minimize the risk of unjustly excluding potential accessible regions for downstream analysis, we used a local threshold value for our selection of ATAC-AVJ regions. We observed that, even with less stringent parameters, genome-wide peak-calling algorithms did not fully call all peaks (we are aware that this observation was done by visually inspecting the ATAC-seq track in the murine *Tbx3* locus and that it is therefore subjective). As such, we used a local, locus-specific threshold value for the selection of peaks -- the entire sequence surpassing the threshold was included and considered as potential RE. A similar approach was used to select ventricle ATAC-peaks, and a random selection of 67 regions from this set was used for the motif enrichment analysis.

From these 67 accessible fetal AVCS regions, 28 overlapped with accessible adult ventricular regions, indeed a fair share of overlap. We have added this to Figure 1. This large portion of overlap can be explained by the fact that although AVCS and ventricle are distinct cell types, both are types of cardiomyocytes and therefore potentially share multiple transcription factors or regulatory machinery components that bind to their genomic location. We tried performing the analysis on regions only accessible in either AVCS or ventricle, however, the number of input regions was too low and underpowered. Furthermore, we note that the previously identified AVCS-specific enhancers Tbx3-eA and Tbx3-eB are accessible in multiple cell types, including our AVCS and ventricle ATAC-seq datasets, yet show highly specific activity in only the AVCS. Excluding regions that are also accessible in the ventricle dataset, or only focusing on the AVCS-specific regions, would omit such potentially strong RE candidates from further analysis. We have included and expanded the Materials and methods section to elaborate more on the inclusion criteria for ATAC peaks and their downstream analysis.

> 6\) The STARR analysis was performed in COS cells to identify regions that activate transcription based on specific TFs previously defined as important for AVC gene expression. As the authors indicate, there is no AVC cell line, requiring use of an unrelated line. None-the-less, the use of COS cells is a significant caveat, and should be discussed clearly in the Discussion. The TF enrichment in this context is a therefore a self-fulfilling prophecy.
>
> The number of human and mouse STARR identified candidates, as well as their overlap, should be described up front.

We have edited the Results section according to the reviewer's suggestion and moved the description on the number of human and mouse STARR REs, and their overlap, up front. We have revised Figure 2 accordingly.

We agree with the reviewer's comments regarding the caveat of using the COS7 cell line for the identification of AVCS-specific regulatory elements. However, in the experiments described in this manuscript, the high transfection efficiency of the COS7 cells allowed us to reach high resolution in the STARR-seq output, which requires large numbers of transfected cells. Indeed, due to low transfection efficiencies, STARR-seq in "atrial" HL1 cells failed. The lack of a non-AVCS-myocardium gene program allowed us to specifically focus on the response of regions in the murine/human TBX3 locus to SG4 or Wnt factors.

The TF enrichment for the respective stimuli could indeed be seen as a self-fulfilling prophecy. However, the aim of this exercise was to validate the cutoff for regulatory activity rather than identify motifs specifically present in these regions, in other words: to see if we, with a rather low threshold for regulatory activity of FC\>1.5 would still extract relevant sequences while minimizing the change to falsely exclude regions. As such, we wanted to assess whether the active regions we identified with the FC\>1.5 threshold would yield relevant sequences, rather than noise caused by inter-experiment variation. Indeed, we found that the active regions in the respective STARR datasets were enriched for binding motifs of the respective factors that we co-transfected the libraries with, indicating the used threshold was justified.

We have revised the Discussion and included some discussion regarding the use of COS-7 cells and the potential caveats. Furthermore, we have revised the Discussion on the interpretation and use of the binding motif enrichment analysis according to the reviewer's comments, also in line with the question of reviewer 2.

> 7\) The description of mouse/human homology for VR1 and VR2 should be described in more detail.

We have added a track displaying sequence conservation in the mouse and human genomes, respectively, to Figure 5, and have added information regarding the sequence homology between mouse and human VR1 and VR2 in the Results section. VR2 also harbors the AVC-specific RE that was functionally and structurally conserved between mouse and human.

> 8\) RE candidate selection is described in Fg3a using a hierarchical approach in schematic form.
>
> It should be possible to use the actual locus, display the individual datasets, and overlay them to present a more accurate description of the chosen REs at the locus.
>
> Figure 3B appears to display data already published. Were any other candidates tested in-vivo?

We agree with the reviewer that the use of the actual locus with the respective datasets would provide a more accurate description of the workflow, and, more importantly, of the filtering/inclusion steps at each step. We have discarded the schematic illustration of the former Figure 3 and revised the figure to show the actual datasets for each step, being: 1) hSTARR-seq data with final regions; 2) human EMERGE predicted enhancers; and 3) mouse orthologous RE candidates, based on fetal AVCS-ATAC-seq and mouse EMERGE enhancer prediction, translated to the human genome. The figure now also shows which regions have been included for downstream analysis at each step.

The LacZ-stained heart showing reporter activity driven by Tbx3-eA from Figure 3B has indeed been published previously, and as such we omitted it from the figure. We believe that the message of this panel, to show that this region (and previously identified Tbx3-eB, not shown here) was marked in all datasets used throughout the pipeline, serves as a validation of our approach and as such we kept the genome browser view of this region and moved it to the Figure 3---figure supplement 1. We did not test other RE candidates in vivo.

> 9\) Several of the candidate risk alleles, examined in luciferase activity in Figure 4C and D, show discordant effects on basal activity and TF-stimulated activity. This should be described and considered. Do the variants alter TF binding sites of known activator or repressor TFs that would help explain this discordance? Do any of the analyzed variants alter TF binding sites of the TF analyzed, which may explain their altered regulatory response to TF expression?

We have added a short paragraph to the Discussion on the discordant direction of effect of variant REs on basal activity and SG4- or Tcf-stimulated activity. "Several of the tested risk alleles (e.g. hRE8, hRE9, hRE18) showed a discordant direction of effect between basal activity in COS-7/HL1 and SG4-/Wnt-stimulated activity. This observation suggests that potentially multiple factors act on these variant REs, with SG4- or Tcf factors counteracting the effect of regulatory networks active in COS-7 or HL1 cells. Although we could not identify specific TF binding motifs affected by the respective SNPs in these REs, studying TF occupancy in more detail specifically in AVCS cells could elaborate on the precise mechanisms through which these variant REs act."

Furthermore, we have analyzed whether the variants in the tested REs disrupt or create transcription factor binding sites using JASPAR. To this end, we took the variant nucleotide and 10 nucleotides both up- and downstream, and used these 21bp sequences as input for transcription factor binding motif recognition in JASPAR using default settings. We did not find any disrupted or de novo created binding motifs this way, although we are aware that the JASPAR binding motif database is incomplete and/or inaccurate as described below (\#11). We also manually analyzed the variant REs for disrupted/de novo created binding motifs, e.g. T-box/E-box motifs, but did not find any. We have added this to the Results section and added a paragraph in the Discussion section.

> 10\) In Figure 6, the schematic shows the location of the TALEN cuts. The authors should delineate VR1 and VR2, as in Figure 5.

We edited Figure 6 such that it shows the location of VR1 and VR2, additional to the location of the CRISPR/TALEN deletion sites according to the reviewer's suggestion.

> 11\) Figure 1C do the authors have insight as to why the Motif consensus for HAND2, TCF3, and TCF4 do not contain a clear E-box motif such as shown for MyoD? The SOX9 Motif also seems out of place with the canonical consensus: CCTTGAG. SMAD 3&4 likewise are reported to bind CAGAC, CAGCC as well as the 5-bp consensus sequence GGC(GC)\|(CG). What is shown in the motif is very different and some discussion of this is warranted there is not confidence that the aforementioned transcription factors would bind these sequences robustly. There is simply low confidence that the algorithm is pulling accurate motif data and the authors should try to address this in the text.

We agree with the reviewer, and have specified interpretations of the Motif analysis. The confidence of such analyses depends on the quality of motifs within the database, which are experimentally derived by different experiments, in various cell types or developmental stages. As such, scanning sequences for motif enrichment using HOMER or other large scale analysis tools should be interpreted with this in mind. Nevertheless, we used the analysis to obtain a global impression of the factors that could be involved in AVCS Tbx3 regulation, while being aware that the output list is far from comprehensive. We have toned down statements regarding the conclusion of this analysis in the Results and Discussion section, and have specified in the Discussion that we used this analysis mainly to obtain an impression of involved factors, and have discussed the caveats of this analysis. Furthermore, we have removed the motif logos from Figure 1C.

> 12\) Figure 2 same issue with consensus data in 2G (note the motif name and the motif do not line up correctly).

Similar to the response to the question above, we have removed the motif logos from Figure 2G and corrected the misalignment of motif name and p-value. Furthermore, similarly to the clarification to the previous question, we have discussed in the manuscript that the motif analysis here was done primarily to see if the regulatory activity of the identified STARR-seq regions indeed correlated with enrichment of motifs for the respective co-transfected factors, rather than to identify novel factors.

> 13\) Figure 3 some clarity in the narration would be helpful. Paragraph one of subsection "Identification of variant REs within VR1 and VR2" discuss 9 candidate REs in VR1 and 13 in VR2. Are these regions supposed to be identifiable in Figure 3A (as is the assumption)? The figure shows 6 candidate REs which resolve to 3 with SNP overlaps comparing the figure to the narration is confusing.

We agree with the reviewer that the narration in this figure might be unclear. Figure 3 served as simplified example to illustrate the workflow we used to identify regulatory elements within VR1 and VR2. As such, the regions shown in Figure 3 do not depict the true REs we identified in this manuscript. We have revised this figure and used the actual data to illustrate the workflow, simultaneously showing which regions have been included for downstream analysis at each step.

> 14\) Figure 6C shows only Tbx3 expression Tbx5 and Med13l expression narrated as being in Figure 6C. Panel G would benefit from slightly enlarged images.

We have corrected the text to include the notion that expression levels of Tbx5 and Med13l have been measured but are not shown in Figure 6C. Furthermore, we have enlarged panel G for clarity, following the reviewer's suggestion.

> 15\) The criteria and datasets used to define the EMERGE regions is not found in this paper nor is there any citation listing where these regions came from. Please clarify.

We have added a paragraph in the Materials and methods section describing the use of EMERGE for the prediction of regulatory elements in both the mouse and human genome. Furthermore, we have added Supplementary Tables 10 and 11 to Supplementary file 1, listing the datasets used by EMERGE to generate a genome-wide prediction track of cardiac enhancers in both the mouse and human genome.

> 16\) What was the criteria used to identify the 9 and 13 (as listed in the text) candidate regulatory elements in VR1/2? Supplementary Table 4 lists only 20 candidate regulatory elements (7 and 13). What happened to hRE1 and hRE2 to exclude them from downstream analysis and inclusion in the table? Were other sites excluded as well? It is also unclear from Figures 2H-K and Figure 3A, and Supplementary Tables 3 and 4 what was used to define the candidate regulatory elements examined in greater detail in Figures 4, Figure 3---figure supplement 1 and S3. For example, hRE13 was not examined in Figures 4C/D or Figure 4---figure supplement 1. Overall, I really like the multi-factor approach to defining candidates; however, the key filtering steps taken to get the final list of candidates needs to be more clearly defined.

We have edited Figure 3, and used the actual *TBX3* locus and data to illustrate the pipeline and the filtering steps that were used to identify candidate REs. Potential regulatory elements have been identified throughout the entire human *TBX3* locus, based on the three approaches/filtering steps shown in revised Figure 3: 1) human STARR-seq activity, 2) human EMERGE enhancer prediction, and 3) mouse orthologous RE candidate regions, based on fetal AVCS-ATAC-seq and mouse EMERGE, translated to the human genome. We then looked at which of these regions were located within VR1 or VR2, and included these regions in Supplementary file 1---Supplementary Table 4. These regions were then overlapped with the GWAS SNPs for PR interval and QRS duration, and the REs overlapping one or more of these SNPs were used for variant haplotype activity testing using transfection/luciferase assays. We have revised the text accordingly to correspond to the revised figure, and hope that this revision clarifies the filtering steps we used to obtain the final list of RE candidates.

hRE1 and hRE2 were initially included as potential regulatory elements. However, their genomic location was outside the set boundaries of VR1 for final downstream analysis and inclusion -- we have corrected the manuscript accordingly, stating that 7 and 13 REs have been identified in VR1 and VR2, respectively.

Due to technical issues we failed to amplify and clone hRE13 from the genomes of the human haplotypes we used. We have added this notion to the manuscript.
